INTRODUCTION: @entity5 constitute a wide variety of disorders having high mortality and morbidity rates. Current protocols for management include surgical intervention, chemotherapy, and radiation which possess numerous adverse effects. Many phytochemicals are available with anticancer properties similar to anticancer drugs. Major benefit of these compounds is apparent lack of @entity137 to normal tissues. Graviola (botanical name: Annona Muricata) contain bioactive compound "annonaceous @entity31800 " known for anticancer activity on @entity5 cell lines. AIMS: To determine @entity137 of Graviola and percentage cell inhibition at G2M phase of cell cycle. SETTINGS AND DESIGN: The @entity137 of aqueous extract of Graviola leaves on @entity957 ( @entity1 ) cell lines at various concentrations evaluated using @entity2454 ( @entity98 ) assay. The percentage of @entity1 cell inhibition at G2M phase of cell cycle determined using flow cytometry. METHODS: Graviola Leaves, American Type Culture Collection @entity1 cell lines were procured from Skanda Laboratories, Bengaluru. The @entity137 of aqueous extract of Graviola on @entity1 cells at various concentrations evaluated using @entity98 assay. The percentage of @entity1 cell inhibition at G2M phase of cell cycle determined using flow cytometry. STATISTICAL ANALYSIS: Statistical analysis was done using one-way ANOVA. RESULTS: @entity98 assay showed statistically significant (P < 0.001) dose-dependent inhibition of @entity1 cell lines by Graviola with IC50 value of 12.42  g/ml. Flow cytometry revealed that Graviola at 25 and 50 g/ml arrested 53.39% and 52.09% cells in G2M phase of cell cycle respectively, which was statistically significant. CONCLUSION: Graviola showed significant cytotoxic activity and percentage of cell inhibition at G2M phase cell cycle against @entity1 cell lines.

Evaluation of XXXX of aqueous extract of Graviola leaves on @entity957 cell-25 cell lines by @entity2454 assay and determination of percentage of cell inhibition at G2M phase of cell cycle by flow cytometry: An in vitro study.

@entity1 :: ('9606', 'Species') :: ['SCC-25'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'cytotoxicity'] @entity31800 :: ('MESH:D054378', 'Chemical') :: ['acetogenins'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Malignancies', 'cancer'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity2454 :: ('MESH:C022616', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide']
@entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']
